Today was quiet. No big deal broke, no government agency ruled, no trial dropped fresh results. The freshest real signal is in the market itself. MindMed, a small psychedelic drug company, saw its stock climb 11.3% — a large jump for a company this size. But there was no announcement to go with it: no trial data, no partnership, no new money. When a small stock moves that much on nothing, it usually means everyday traders chasing momentum, not serious investors deciding the company is safer to bet on. Meanwhile the bigger names barely moved — Compass, the field's most-watched company, slipped 2.1%, and atai sat flat.
Beneath the day-to-day price swings, one clear thread runs through everything. The whole psychedelic field is now standing at a single doorway: durability. It is easy to show that a psilocybin dose can lift someone out of deep depression for a short while. The hard question — the one that decides whether these treatments become real medicine or stay a hopeful experiment — is whether that lift lasts. Does the depression stay away, or does it creep back? Compass is running the trial that everyone is watching for this answer. When those results come, they will move the entire field far more than any quiet stock spike. There is a similar tug-of-war happening with the recent news that psilocybin helps people "live in the moment." Careful scientists are already reminding everyone that a brief change in the brain during a trip is not the same as lasting healing. That caution is not the enemy of progress — it is the guardrail that makes progress trustworthy.
Behind all of this are people who cannot wait forever. Someone with depression that no other drug has touched does not care about a stock chart. They care whether the treatment they hear about will actually give them a life back — and keep it. A veteran carrying the weight of what they survived is watching whether the only political path left, quietly attaching psychedelic help to bills that fund veterans' care, will finally open a door for them. The honest, hopeful truth is this: the field is slowing down in exactly the right way. It is asking the harder question — does the healing hold? — because that is the question that earns lasting trust. And the treatment that proves it lasts is the one that changes millions of lives, not just headlines. That proof is coming closer, not further away.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
What is being called in cannot be called back.
68%
Mind Medicine's surprise stock jump will likely fade fast
Mind Medicine (a psychedelic drug company) saw its stock jump 11.3% with no real news — no new drug results, no partnership announcement, nothing. Historically, when a small, thinly-traded stock like this jumps without a good reason, it tends to drift back down within weeks. If this prediction is right, the stock gives back at least half that gain by September 20, 2026.
→ The stock jumped for no clear reason, and there's a better-than-even chance it gives most of that back within three weeks.
Resolves: 2026-09-20 · Global
MARKETS
the precise call ▾
MMED's catalyst-free 11.3% spike retraces at least half within three weeks.. Catalyst-free spikes in thin psychedelic names mean-revert. No confirming clinical or partnership news accompanied this move; it's momentum/retail, not de-risking. Anchored to today's specific 11.3% MMED move. || RESOLUTION RULE: YES if MIND Medicine (MNMD/MMED) closing price on 2026-09-20 has retra
62%
Compass Pathways' depression drug data could shake the whole sector
Compass Pathways is testing a psilocybin-based treatment called COMP360 for people with hard-to-treat depression. When Compass releases new data about how long the treatment's benefits last — or whether patients relapse — it tends to send not just Compass's stock but the entire psychedelic medicine sector swinging sharply. This prediction says that swing will be at least 8% up or down on the day the news drops.
→ Compass Pathways' upcoming results on whether psilocybin benefits last could move the entire psychedelic sector by 8% or more in a single day.
Resolves: 2026-12-01 · Global
MARKETS
the precise call ▾
CMPS's next COMP360 durability disclosure moves the psychedelic basket ≥8% intraday.. CMPS is the sector's de-risking bellwether; the TRD relapse/durability data is the catalyst institutions are positioned around. Correlated peers (MNMD, ATAI, GH Research) move on CMPS binary events. || RESOLUTION RULE: YES if Compass Pathways (CMPS) issues a COMP360 durability/relapse data disclosur
60%
Scientists will challenge the 'live-in-the-moment' psilocybin brain study
A recent study found that psilocybin changes how brain networks communicate in ways linked to being more present and in the moment. But scientists are likely to quickly publish responses pointing out that seeing something happen in the brain right after taking a drug doesn't prove the person stays better weeks or months later. This kind of critique is a normal, healthy part of science.
→ Interesting brain findings from psilocybin studies will likely be met with published reminders that a short-term brain change doesn't guarantee a long-term mental health benefit.
Resolves: 2026-11-01 · Global
RESEARCH
the precise call ▾
The 'psilocybin live-in-the-moment' finding draws a published mechanistic caveat separating acute network effects from durable clinical change.. Acute neuroimaging effects don't equal lasting therapeutic change. Anchored to today's specific psilocybin acute-network finding; critics reliably publish durability caveats within weeks. || RESOLUTION RULE: YES if, by 2026-11-01, a peer-reviewed journal, preprint (bioRxiv/medRxiv/PsyArXiv), or publ
60%
Ketamine depression study will show quick relief but raise long-term concerns
A new study on esketamine — a fast-acting drug already approved for depression — is expected to show it works well at cutting depression symptoms quickly. But the results will likely also highlight a catch: symptoms can come back, and it's unclear how to keep people well long-term. This split result — 'yes it works, but...' — matters because it shapes what doctors are allowed to say and prescribe.
→ The esketamine study will likely confirm it works fast for depression but will also raise a serious question about how to stop people from sliding back afterward.
Resolves: 2026-11-15 · Global
CLINICAL
the precise call ▾
The esketamine MDD study reports statistically significant acute symptom reduction while flagging durability/relapse as a labeling concern.. Esketamine has an established regulatory track; acute efficacy wins are reliable, but maintenance dosing and relapse are where labels get contested. Split outcome is the specific, testable claim. || RESOLUTION RULE: YES if, by 2026-11-15, topline results of the referenced esketamine MDD study are pu
60%
Psychedelic research wins in Congress will come through veterans' bills, not standalone laws
There's broad political agreement that veterans deserve better mental health care, and some lawmakers want to use that goodwill to fund psychedelic therapy research. The prediction is that any real progress on psychedelics in Congress by end of 2026 will happen quietly, tucked inside military spending or veterans' care bills — not through a big standalone law dedicated to psychedelics. That's just how Washington works right now.
→ Psychedelics won't get their own big federal law this cycle — but they might sneak forward by hitching a ride on veterans' mental health legislation.
Resolves: 2026-12-31 · US
LEGISLATION
the precise call ▾
Psychedelic provisions advance this cycle only as veteran-mental-health riders (NDAA/appropriations), not standalone bills.. Standalone federal action is stalled; the only viable path with bipartisan cover is riding veteran mental-health vehicles. Specific mechanism claim, not a generic no-federal-action baseline. || RESOLUTION RULE: YES if, by 2026-12-31, any psychedelic-related provision (e.g., research authorization, V